Use of Proton Pump Inhibitors With Dexamethasone in Patients With COVID-19 Pneumonia: Contributions to Long-Term Polypharmacy.

Cureus · 2022 · PMC9156393 · PMID 35663709

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Previous studies have estimated the relative risk of developing one or more of these gastrointestinal adverse effects as varying from 1.1 (not significant) to 1.5 (marginally significant) [ 2 , 3 ].

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.